JP2025513501A - 凍結乾燥組成物 - Google Patents

凍結乾燥組成物 Download PDF

Info

Publication number
JP2025513501A
JP2025513501A JP2024562210A JP2024562210A JP2025513501A JP 2025513501 A JP2025513501 A JP 2025513501A JP 2024562210 A JP2024562210 A JP 2024562210A JP 2024562210 A JP2024562210 A JP 2024562210A JP 2025513501 A JP2025513501 A JP 2025513501A
Authority
JP
Japan
Prior art keywords
aqueous composition
pharma
acceptable salt
reconstituted
rilpivirine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513501A5 (cg-RX-API-DMAC7.html
Inventor
ヴェッキ,シモーネ
コロンボ,ミリアム
サーガー,アン ギルバート ピー デ
ポール エム ヴァーストラーテン,マキシム
キャロライン エフ ヴァーヴールト,イワン
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2025513501A publication Critical patent/JP2025513501A/ja
Publication of JP2025513501A5 publication Critical patent/JP2025513501A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2024562210A 2022-04-22 2023-04-24 凍結乾燥組成物 Pending JP2025513501A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263333557P 2022-04-22 2022-04-22
US63/333,557 2022-04-22
EP22173920.4 2022-05-17
EP22173920 2022-05-17
PCT/EP2023/060686 WO2023203255A1 (en) 2022-04-22 2023-04-24 Freeze dried compositions

Publications (2)

Publication Number Publication Date
JP2025513501A true JP2025513501A (ja) 2025-04-24
JP2025513501A5 JP2025513501A5 (cg-RX-API-DMAC7.html) 2026-05-08

Family

ID=86330122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562210A Pending JP2025513501A (ja) 2022-04-22 2023-04-24 凍結乾燥組成物

Country Status (7)

Country Link
US (1) US20250275967A1 (cg-RX-API-DMAC7.html)
EP (1) EP4511007A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513501A (cg-RX-API-DMAC7.html)
CN (1) CN119403545A (cg-RX-API-DMAC7.html)
CA (1) CA3249784A1 (cg-RX-API-DMAC7.html)
TW (2) TW202406551A (cg-RX-API-DMAC7.html)
WO (2) WO2023203257A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
BRPI0715113A2 (pt) * 2006-07-26 2013-06-04 Sandoz Ag Sandoz Sa Sandoz Ltd formulaÇço de caspofungina
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
GB2513060B (en) * 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
HRP20201241T1 (hr) * 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
WO2018013673A1 (en) * 2016-07-13 2018-01-18 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
WO2022109555A1 (en) 2020-11-17 2022-05-27 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection

Also Published As

Publication number Publication date
EP4511007A1 (en) 2025-02-26
WO2023203255A1 (en) 2023-10-26
CN119403545A (zh) 2025-02-07
WO2023203257A1 (en) 2023-10-26
US20250275967A1 (en) 2025-09-04
TW202408580A (zh) 2024-03-01
CA3249784A1 (en) 2023-10-26
TW202406551A (zh) 2024-02-16

Similar Documents

Publication Publication Date Title
EP2723371B1 (en) Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
JP7150804B2 (ja) プラミノーゲンを含む医薬組成物及びその使用
US20090298743A1 (en) Hydrophobic compositions containing reconstitution enhancer
KR20090023703A (ko) Tmc278의 수성 현탁제
JP2007512266A (ja) Egf受容体に対する抗体を含む医薬製剤
JP6869255B2 (ja) 凍結医薬製剤およびその使用
US20250275967A1 (en) Freeze dried compositions
JP2025513502A (ja) 液体組成物
CN116744903A (zh) 包含二苯基吡嗪衍生物的药物组合物
JP2023549837A (ja) 疾患又は障害の治療又は予防
US20130131089A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
JP2024540465A (ja) 溶解試験
CA3268292A1 (en) LONG-ACTING FORMULAS
WO2024068693A1 (en) Long-acting formulations
TW202408526A (zh) 治療或預防hiv感染(一)
WO2011137459A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
CN116437923A (zh) Hiv感染的治疗或预防
HK1175984B (en) Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260424